Abstract | AIM: METHODS: RESULTS: Acute treatment with taspoglutide reduced glucose excursion and increased insulin response during oGTT. In chronically treated rats, glucose excursion and levels of GIP, PYY and triglycerides during oGTT on day 21 were significantly reduced. Postprandial glucose levels were significantly lower than vehicle controls by day 15. A significant reduction in body weight gain was noticed by day 8, and continued until the end of the study when body weight was approximately 7% lower in rats treated with taspoglutide compared to vehicle. Glycaemic control (increased levels of 1,5-anhydroglucitol) and insulin sensitivity (Matsuda index) were improved by taspoglutide treatment. CONCLUSIONS:
|
Authors | E Sebokova, A Bénardeau, U Sprecher, S Sewing, L Tobalina, C Migliorini |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 12
Issue 8
Pg. 674-82
(Aug 2010)
ISSN: 1463-1326 [Electronic] England |
PMID | 20590744
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Peptides
- taspoglutide
- Glucagon-Like Peptide 1
|
Topics |
- Animals
- Blood Glucose
- Body Weight
(drug effects)
- Diabetes Mellitus, Type 2
(drug therapy)
- Glucagon-Like Peptide 1
(analogs & derivatives, pharmacology, therapeutic use)
- Glucose Tolerance Test
- Homeostasis
(drug effects)
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Peptides
(pharmacology, therapeutic use)
- Postprandial Period
- Rats
- Rats, Zucker
|